Engineering blood outgrowth endothelial cells to optimize endothelial nitric oxide synthase and extracellular matrix production for coating of blood contacting surfaces
Source abstract
Abstract
Coverage of blood contacting surfaces by a functional endothelial layer is likely required to induce and maintain homeostasis. Blood outgrowth endothelial cells (BOECs), cultured from human peripheral blood monocytes, are readily available and functional autologous endothelial source that may represent a reasonable alternative to vascular derived cells. Endothelial nitric oxide synthase (eNOS) produces NO, an important factor that regulates homeostasis at the blood-contacting surface. We found that BOECs express markedly lower levels of eNOS protein (34% ± 13%, Western blot) and mRNA (29% ± 17%, qRT-PCR), as well as exhibiting reduced activity (49% ± 18%, Nitrite analysis) when compared to human umbilical vein endothelial cells (HUVECs) and human aortic endothelial cells. HUVECs grown on fibronectin, type I collagen, or laminin -coated surfaces exhibited significant reduction of eNOS mRNA and protein expression. However, no decrease in eNOS levels was observed in BOECs. Interestingly BOECs expressed significantly higher Collagen (Col) I compared to HUVECs, and blocking Col I synthesis significantly enhanced eNOS expression in BOECs. Inhibition of β1 integrin, focal adhesion kinase (FAK), or actin polymerization increased eNOS in both BOECs and HUVECs suggesting involvement of a signaling pathway culminating in stabilization of the cytoskeleton. Finally, we demonstrated that a Rho-associated protein kinases (ROCK) inhibitor, as a disruptor of actin stabilization, enhanced both eNOS expression and bioactivity. Taken together, our findings demonstrate that cell-ECM interactions are fundamental to the regulation of eNOS in BOECs and suggest that disruption of key intracellular pathways (such as ROCK) may be necessary to enhance functional activity of an endothelialized surface. STATEMENT OF SIGNIFICANCE: Development of biocompatible blood-contacting biomaterial surfaces has not been possible to date, leading many investigators to believe that a complete autologous endothelial layer will be necessary. Blood outgrowth endothelial cells (BOECs), cultured from human peripheral blood monocytes, are readily available and functional autologous endothelial source. Endothelial nitric oxide synthase (eNOS) produces NO, an important factor that regulates homeostasis at the blood-contacting surface. In this study, we show that eNOS displays limited expression in cultured BOECs. We further demonstrate that a strong negative regulation of eNOS is mediated by collagen substrates and that treatment with ROCK inhibitor could enhance both eNOS expression and activity in BOECs and help to rapidly establish a functional autologous endothelial layer on cardiovascular biomaterials.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Angiogenesis and VEGF in Cancer · Nitric Oxide and Endothelin Effects · Cell Adhesion Molecules Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (60)
Show source-provided references
1. Eight years of clinical endothelial cell transplantation. Closing the gap between prosthetic grafts and vein grafts10.1097/00002480-199709000-00034 ↗
2. Clinical autologous in vitro endothelialization of 153 infrainguinal ePTFE grafts10.1016/S0003-4975(01)02555-3 ↗
3. Clinical autologous in vitro endothelialization of infrainguinal ePTFE grafts in 100 patients: a 9-year experience10.1016/S0039-6060(99)70025-5 ↗
4. Above-knee femoropopliteal bypass grafting using endothelial cell seeded PTFE grafts: five-year clinical experience10.1016/S0890-5096(06)60447-0 ↗
5. Clinical experience with autologous endothelial cell-seeded polytetrafluoroethylene coronary artery bypass grafts10.1067/mtc.2000.106327 ↗
6. Multicenter phase I/II trial of the safety of allogeneic endothelial cell implants after the creation of arteriovenous access for hemodialysis use: the v-health study10.1016/j.jvs.2009.07.108 ↗
7. Prospective clinical study with in vitro endothelial cell lining of expanded polytetrafluoroethylene grafts in crural repeat reconstruction10.1016/0741-5214(92)90192-B ↗
8. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells10.1093/emboj/18.14.3964 ↗
9. VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease10.1016/S0003-4975(00)01633-7 ↗
10. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization10.1073/pnas.97.7.3422 ↗
11. Derivation of human peripheral blood derived endothelial progenitor cells and the role of osteopontin surface modification and eNOS transfection10.1016/j.biomaterials.2013.06.003 ↗
12. Transcript analysis reveals a specific HOX signature associated with positional identity of human endothelial cells10.1371/journal.pone.0091334 ↗
13. Characterization of umbilical cord blood-derived late outgrowth endothelial progenitor cells exposed to laminar shear stress10.1089/ten.tea.2008.0444 ↗
14. Toward engineering a human neoendothelium with circulating progenitor cells10.1002/stem.275 ↗
15. Shear stress responses of adult blood outgrowth endothelial cells seeded on bioartificial tissue10.1089/ten.tea.2011.0055 ↗
16. Umbilical cord blood derived endothelial progenitor cells for tissue engineering of vascular grafts10.1016/j.athoracsur.2004.06.052 ↗
17. Engineering an antiplatelet adhesion layer on an electrospun scaffold using porcine endothelial progenitor cells10.1002/jbm.a.33040 ↗
18. Canine endothelial progenitor cell-lined hybrid vascular graft with nonthrombogenic potential10.1016/S0022-5223(02)73264-9 ↗
19. Use of autologous blood-derived endothelial progenitor cells at point-of-care to protect against implant thrombosis in a large animal model10.1016/j.biomaterials.2011.07.066 ↗
20. Human endothelial progenitor cell-seeded hybrid graft: proliferative and antithrombogenic potentials in vitro and fabrication processing10.1089/107632703762687609 ↗
21. Blood outgrowth endothelial cells alter remodeling of completely biological engineered grafts implanted into the sheep femoral artery10.1007/s12265-013-9539-z ↗
22. The importance of the endothelium in atherothrombosis and coronary stenting10.1038/nrcardio.2012.64 ↗
23. The 1991 ULF von Euler lecture. the l-arginine: nitric oxide pathway10.1111/j.1748-1716.1992.tb09359.x ↗
24. Role of endothelial nitric oxide synthase in endothelial cell migration10.1161/01.ATV.19.5.1156 ↗
25. eNOS uncoupling in cardiovascular diseases–the role of oxidative stress and inflammation10.2174/13816128113196660748 ↗
26. Endothelial nitric oxide synthase in vascular disease: from marvel to menace10.1161/CIRCULATIONAHA.105.602532 ↗
27. Fibronectin coating of expanded polytetrafluoroethylene (ePTFE) grafts and its role in endothelial seeding10.1111/j.1525-1594.1990.tb01590.x ↗
28. The effect of varying fibronectin concentration on the attachment of endothelial cells to polytetrafluoroethylene vascular grafts10.1016/0741-5214(90)90100-O ↗
29. Human vascular endothelial cell attachment and growth inhibition by type V collagen10.1016/0741-5214(93)90115-3 ↗
30. Decreased nitric oxide synthesis in human endothelial cells cultured on type I collagen10.1161/01.RES.0000012445.68979.9D ↗
31. Negative modulation of eNOS by laminin involving post-translational phosphorylation10.1002/jcp.21659 ↗
32. Modulation of endothelial nitric oxide synthase by fibronectin10.1007/s11010-008-9967-2 ↗
33. The extracellular matrix is a novel attribute of endothelial progenitors and of hypoxic mature endothelial cells10.1096/fj.12-209296 ↗
34. Integrins and extracellular matrix in mechanotransduction10.1101/cshperspect.a005066 ↗
35. Rho-kinase/ROCK: a key regulator of the cytoskeleton and cell polarity10.1002/cm.20472 ↗
36. Rho kinase as a therapeutic target in cardiovascular disease10.2217/fca.11.51 ↗
37. ROCKs as therapeutic targets in cardiovascular diseases10.1586/14779072.3.3.441 ↗
38. Innate immunity in the therapeutic actions of endothelial progenitor cells in pulmonary hypertension10.1165/rcmb.2009-0152OC ↗
39. Molecular analysis of endothelial progenitor cell (EPC) subtypes reveals two distinct cell populations with different identities10.1186/1755-8794-3-18 ↗
40. Late outgrowth endothelial cells resemble mature endothelial cells and are not derived from bone marrow10.1002/stem.1280 ↗
41. Fetal and adult fibroblasts display intrinsic differences in tendon tissue engineering and regeneration10.1038/srep05515 ↗
42. ILK, pinch and parvin: the tIPP of integrin signalling10.1038/nrm1789 ↗
43. Integrin-linked protein kinase regulates fibronectin matrix assembly, E-cadherin expression, and tumorigenicity10.1074/jbc.273.1.528 ↗
44. An inhibitory role for FAK in regulating proliferation: a link between limited adhesion and RHOA-ROCK signaling10.1083/jcb.200510062 ↗
45. Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration10.1242/jcs.112.16.2677 ↗
46. Role of focal adhesion kinase in flow-induced dilation of coronary arterioles10.1161/01.ATV.0000188511.84138.9b ↗
47. Role of FAK phosphorylation in hypoxia-induced hMSCS migration: involvement of vegf as well as mapks and eNOS pathways10.1152/ajpcell.00418.2009 ↗
48. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase10.1073/pnas.95.15.8880 ↗
49. Neuroprotection mediated by changes in the endothelial actin cytoskeleton10.1172/JCI9639 ↗
50. Actin cytoskeleton organization and posttranscriptional regulation of endothelial nitric oxide synthase during cell growth10.1161/01.RES.0000138953.21377.80 ↗
51. Regulation of endothelial nitric oxide synthase by the actin cytoskeleton10.1152/ajpcell.00248.2002 ↗
52. Distinct roles for ROCK1 and ROCK2 in the regulation of cell detachment10.1038/cddis.2013.10 ↗
53. Mechanism underlying increased eNOS expression and neuroprotection in mice with targeted deletion of ROCK2
54. Interaction of hyperlipidemia and reactive oxygen species: insights from the lipid-raft platform10.4330/wjc.v8.i12.689 ↗
55. The future challenge of reactive oxygen species (ROS) in hypertension: from bench to bed side10.3390/ijms18091988 ↗
56. Nitric oxide: a key factor behind the dysfunctionality of endothelial progenitor cells in diabetes mellitus type-210.1093/cvr/cvq412 ↗
57. Nitric oxide and superoxide dismutase modulate endothelial progenitor cell function in type 2 diabetes mellitus10.1186/1475-2840-8-56 ↗
58. Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes10.2337/db06-0699 ↗
59. Inorganic arsenic activates reduced NADPH oxidase in human primary macrophages through a rho kinase/p38 kinase pathway10.4049/jimmunol.180.9.6010 ↗
60. The function of rho-associated kinases ROCK1 and ROCK2 in the pathogenesis of cardiovascular disease10.3389/fphar.2015.00276 ↗